Table 1.
Patient, treatment, and disease characteristics.
| Overall Cohort (N) | <10 yr. survival | 10+ yr. survival | P value (<10 yr. vs 10+ yr. survival) | |
|---|---|---|---|---|
| Patients | 85 | 73 | 12 | |
| Age | 0.69 | |||
| <50 | 38 | 32 | 6 | |
| 50+ | 47 | 41 | 6 | |
| Sex | 0.07 | |||
| Male | 61 | 52 | 9 | |
| Female | 24 | 21 | 3 | |
| Race | 0.11 | |||
| White | 76 | 65 | 11 | |
| Unknown | 4 | 4 | 0 | |
| Other | 3 | 3 | 0 | |
| Black or African American | 1 | 1 | 0 | |
| Asian Chinese | 1 | 0 | 1 | |
| Prior Auto SCT(s) | 0.03* | |||
| 0 | 4 | 2 | 2 | |
| 1 | 63 | 53 | 10 | |
| 2 | 18 | 18 | 0 | |
| Years from MM Dx to Allo SCT | 0.54 | |||
| 0–2 | 20 | 17 | 3 | |
| 2–5 | 48 | 40 | 8 | |
| 5+ | 17 | 16 | 1 | |
| Years from Auto SCT1 to Allo SCT | N = 81 | N = 71 | N = 10 | 0.33 |
| 0–2 years | 45 | 38 | 7 | |
| 2+ years | 36 | 33 | 3 | |
| Auto SCT1 Response at Day 100 | N = 70 | N = 60 | N = 10 | 0.39 |
| CR | 30 | 26 | 4 | |
| VGPR | 10 | 7 | 3 | |
| PR | 25 | 23 | 2 | |
| Progression | 5 | 4 | 1 | |
| Years from Auto SCT2 to Allo SCT | (N = 18) | N = 18 | N = 0 | — |
| 0–2 years | 14 | 14 | — | |
| 2+ years | 4 | 4 | — | |
| Auto SCT2 Response at Day 100 | (N = 10) | (N = 9) | (N = 1) | 0.86 |
| CR | 1 | 1 | 0 | |
| VGPR | 1 | 1 | 0 | |
| PR | 6 | 5 | 1 | |
| Progression | 2 | 2 | 0 | |
| Allo Date | 0.03* | |||
| 2000–2010 | 46 | 36 | 10 | |
| 2011- | 39 | 37 | 2 | |
| Response Status Going Into Allo SCT (N = 78) | 0.58 | |||
| CR | 14 | 10 | 4 | |
| VGPR | 11 | 10 | 1 | |
| PR | 22 | 21 | 1 | |
| Stable Disease | 7 | 5 | 2 | |
| Progression | 24 | 22 | 2 | |
| Cytogenetic Risk (N = 80) | 0.17 | |||
| Standard | 53 | 43 | 10 | |
| High risk | 27 | 25 | 2 | |
| Transplant Intensity | 0.21 | |||
| MA | 47 | 38 | 9 | |
| RIC | 26 | 23 | 3 | |
| NMA | 12 | 12 | 0 | |
| Transplant course: | ||||
| Standalone MA allo SCT | 47 | 38 | 9 | |
| Standalone RIC allo SCT | 15 | 14 | 1 | |
| Standalone NMA allo SCT | 6 | 6 | 0 | |
| Upfront auto SCT to RIC allo SCT | 3 | 3 | 0 | |
| Auto SCT to RIC (or NMA) allo SCT for relapse | 14 | 12 | 2 | |
| Acute GVHD | 0.97 | |||
| Present | 50 | 43 | 7 | |
| Absent | 35 | 30 | 5 | |
| Chronic GVHD | 0.69 | |||
| Present | 38 | 32 | 6 | |
| Absent | 47 | 41 | 6 | |
| Lines of Therapy Before Allo SCT | 0.17 | |||
| 1–3 | 21 | 18 | 3 | |
| 4–6 | 48 | 39 | 9 | |
| 7+ | 16 | 16 | 0 | |
| Donor Type | (N = 84) | 0.94 | ||
| PBSC Related | 50 | 43 | 7 | |
| PBSC Unrelated | 32 | 27 | 5 | |
| Single UC Unrelated | 1 | 1 | 0 | |
| Double UC Unrelated | 1 | 1 | 0 | |
| Median (years) | ||||
| Age at allo transplant | 51.2 | 51.2 | 50.3 | 0.71 |
| Time from MM diagnosis to allo SCT | 2.65 | 2.77 | 2.48 | 0.22 |
| Time from auto SCT1 to allo SCT | 1.88 | 1.88 | 1.69 | 0.15 |
| Time from auto SCT2 to allo SCT | 0.54 | 0.54 | — | — |
| Lines of therapy prior to Allo SCT | 4 | 4 | 4 | — |
| OS | 1.86 | 1.14 | 13.0 | <0.01* |
| PFS | 0.71 | 0.59 | 10.4 | <0.01* |
| 1-year treatment-related mortality (TRM) | 20 | 20 | — | — |
Auto SCT autologous stem cell transplant.
Allo SCT allogeneic stem cell transplant.
CR complete response.
VGPR very good partial response.
PR partial response.
MA myeloablative.
RIC reduced-intensity chemotherapy.
NMA nonmyeloablative.
GVHD graft-versus host disease.
PBSC peripheral blood stem cell.
UC umbilical cord.
*p < 0.05.
Bold entries denote statistically significant p values.